Latest market price
13.21
+0.06+0.46%
OverviewShort InterestFilings
NVCRQT41Novocure Ltd·NASDAQ
13.21+0.46%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
BFLY-3.91%$6.14CNMD+5.19%$46.59ESTA-2.23%$61.07TNDM-2.30%$18.67INSP-1.31%$67.21ENOV+3.57%$20.62AORT+4.43%$23.58ATEC+3.84%$7.31
Snapshot
Index—P/E—EPS (ttm)-1.06Insider Own3.60%Shs Outstand116.45MPerf Week-8.26%
Market Cap1.54BForward P/E—EPS next Y-0.66Insider Trans-1.31%Shs Float96.81MPerf Month-11.58%
Enterprise Value1.31BPEG—EPS next Q-0.22Short Float13.25%Perf Quarter-18.81%
Income-121.00MP/S2.12EPS this Y—Short Ratio8.83Perf Half Y-21.97%
Sales725.00MP/B4.38EPS next Y—ROA-14.69%Short Interest12.82MPerf YTD2.17%
Book/sh3.01P/C3.32EPS next 5Y—ROE-35.81%52W High21.45 -38.41%Perf Year3.04%
Cash/sh3.98P/FCF—EPS past 3/5Y—ROIC-19.92%52W Low9.82 34.52%Perf 3Y1.46%
Dividend Est.—EV/EBITDA—Sales past 3/5Y6.78% 5.80%Gross Margin77.02%Volatility6.80% 5.03%Perf 5Y-88.93%
Dividend TTM—EV/Sales1.80EPS Y/Y TTM—Oper. Margin-17.17%ATR (14)0.79Perf 10Y93.13%
Dividend Ex-Date—Quick Ratio2.34Sales Y/Y TTM12.93%Profit Margin-16.78%RSI (14)34.79Recom2.47
Dividend Gr. 3/5Y—Current Ratio2.49EPS Q/Q72.73%SMA20-8.39%Beta1.11Target Price26.00
Payout0.00%Debt/Eq0.66Sales Q/Q15.57%SMA50-15.92%Rel Volume1.15Prev Close13.15
Employees1,605LT Debt/Eq0.59EarningsFeb 25SMA200-10.82%Avg Volume1.44MPrice13.21
IPO DateOct 02, 2015Option/ShortYes / YesEPS/Sales Surpr.61.68% 6.10%Net Debt/EBITDA—Volume1,647,264Change0.46%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-24-26ReiteratedWedbushNeutral$20
Jul-23-26ReiteratedH.C. WainwrightBuy$46 → $52
Jun-18-26ReiteratedHC Wainwright & Co.Buy$47 → $46
Feb-12-26ReiteratedHC Wainwright & Co.Buy$39 → $47
Jan-13-26ReiteratedHC Wainwright & Co.Buy$42 → $39
Jan-05-26ReiteratedEvercore ISIOutperform$22 → $20
Oct-30-25ReiteratedHC Wainwright & Co.Buy$30 → $42
Jul-25-25DowngradeWells FargoOverweight → Equal Weight$15
Dec-02-24UpgradeEvercore ISI GroupIn Line → Outperform$15 → $30
Oct-16-24UpgradeHC Wainwright & Co.Neutral → Buy$24 → $30
Latest News· Times ET
Nov-02-26
Nov-02-2610:16AM
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stockzacks.com
Nov-01-26
Nov-01-2609:23PM
NovoCure: 3 Key Takeaways for Long-Term Investorsfool.com
Oct-29-26
Oct-29-2607:58PM
NovoCure Limited (NVCR) Q3 2026 Earnings Call Transcriptseekingalpha.com
04:15PM
NovoCure Q3 Earnings Call Highlightsmarketbeat.com
09:36AM
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimateszacks.com
09:19AM
Novocure (NASDAQ:NVCR) Q3 Results Beat Estimates as Raised Outlook Lifts StockChartMill
07:00AM
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidancebusinesswire.com
Oct-28-26
Oct-28-2607:00AM
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreementbusinesswire.com
Oct-19-26
Oct-19-2606:14AM
NovoCure (NASDAQ:NVCR) and Ambu A/S (OTCMKTS:AMBBY) Head to Head Contrastdefenseworld.net
Oct-13-26
Oct-13-2611:30AM
Novocure: A Mispriced Cash-Generating Biotech With Upside Potentialseekingalpha.com
Oct-12-26
Oct-12-2610:15AM
Reviewing NeurAxis (NASDAQ:NRXS) and NovoCure (NASDAQ:NVCR)defenseworld.net
Oct-11-26
Oct-11-2605:34AM
Critical Survey: Medline (NASDAQ:MDLN) & NovoCure (NASDAQ:NVCR)defenseworld.net
Oct-10-26
Oct-10-2602:20AM
The Bull Case For NovoCure (NVCR) Could Change Following Japan’s Optune Pax Pancreatic Cancer ApprovalYahoo
Oct-01-26
Oct-01-2609:00AM
Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancerbusinesswire.com
05:04AM
Japan’s Ministry Of Health, Labour And Welfare Approves Novocure's Optune Pax To Treat Adults With Unresectable Locally Advanced Pancreatic CancerBenzinga
Company

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue725655605509—————
Cost of Goods Sold Incl. D&A167167137128—————
Gross Profit558488468381—————
Selling, General and Administrative Excl. Other455418429391—————
Research and Development228225210223—————
Other Operating Expense1-101—————
Operating Income-124-154-170-233—————
Interest Expense90125—————
Unusual Expense
—————————
Non-Operating Income (Expense)2185146—————
Net Income Before Taxes-130-136-131-192—————
Income Taxes-803715—————
Consolidated Net Income-121-136-169-207—————
Net Income From Continuing Operations-121-136-169-207—————
Net Income-121-136-169-207—————
EPS (Recurring)-1.06-1.22-1.56-1.95—————
EPS (Basic, Before Extraordinaries)-1.06-1.22-1.56-1.95—————
EPS (Diluted)-1.06-1.22-1.56-1.95—————
EBITDA-104-122-110-177—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio2.132.195.323.11—————
Gross Margin76.9774.5077.3674.85—————
Operating Margin-17.10-23.51-28.10-45.78—————
Net Margin-16.69-20.76-27.93-40.67—————
Shares Outstanding117111108106—————
Market Capitalization1,5461,4353,2181,583—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$21.48$18.25$15.01$11.77$8.54● Close Price0.00M0.51M1.01M1.52M2.02MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Leonard Frank XChief Executive OfficerJun 04 '26Sale17.9334,273614,635459,520Jun 05
LEUNG GABRIELDirectorJun 02 '26Sale15.772,94546,44589,499Jun 03
Stafford KristinDirectorJun 02 '26Sale15.772,94546,44511,324Jun 03
Ocean Allyson JDirectorJun 02 '26Sale15.772,94546,44511,324Jun 03
Scannell Timothy JDirectorJun 02 '26Sale15.772,94546,44514,288Jun 03
HILLEMAN JERYL LDirectorJun 02 '26Sale15.772,94546,44513,861Jun 03
VERNON W ANTHONYDirectorJun 02 '26Sale15.772,94546,445197,657Jun 03
Hung DavidDirectorJun 02 '26Sale15.772,94546,44520,465Jun 03
VERNON W ANTHONYDirectorApr 28 '26Option Exercise11.3921,500244,885200,602Apr 28
Paravasthu MukundChief Operating OfficerMar 05 '26Sale13.7743,246595,67072,832Mar 05
Leupin NicolasFormer Chief Medical OfficerMar 04 '26Sale13.311,10014,636102,979Mar 05
Leonard Frank XChief Executive OfficerMar 04 '26Sale13.315,60774,603493,793Mar 05
Paravasthu MukundChief Operating OfficerMar 04 '26Sale13.315,37771,543116,078Mar 05
Weinberg UriChf Medical and Innovation OfrMar 04 '26Sale13.316,41285,314267,190Mar 05
Puri Michal NathChief Human Resources OfficerMar 04 '26Sale13.311,10014,636201,322Mar 05
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.